BMO Capital Markets Cuts Doximity (NYSE:DOCS) Price Target to $20.00

Doximity (NYSE:DOCS) had its price target cut by BMO Capital Markets from $25.00 to $20.00 in a research report sent to investors on Thursday morning, MarketBeat reports. They currently have a market perform rating on the stock.

Several other equities research analysts have also recently commented on the stock. Barclays lowered their price target on shares of Doximity from $63.00 to $38.00 and set an “overweight” rating for the company in a research report on Wednesday, February 11th. Morgan Stanley lowered their price target on shares of Doximity from $49.00 to $35.00 and set an “overweight” rating for the company in a research report on Thursday. Mizuho lowered their price target on shares of Doximity from $34.00 to $26.00 and set a “neutral” rating for the company in a research report on Thursday. Zacks Research upgraded shares of Doximity from a “strong sell” rating to a “hold” rating in a research report on Tuesday, April 21st. Finally, JPMorgan Chase & Co. lowered their price target on shares of Doximity from $40.00 to $33.00 and set a “neutral” rating for the company in a research report on Friday, February 20th. Two analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating, thirteen have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $30.62.

Doximity Stock Performance

Shares of NYSE:DOCS opened at $18.93 on Thursday. Doximity has a one year low of $17.15 and a one year high of $76.51. The business’s 50 day simple moving average is $23.94. The firm has a market cap of $3.50 billion, a PE ratio of 19.12, a price-to-earnings-growth ratio of 1.35 and a beta of 1.36.

Doximity declared that its Board of Directors has initiated a share buyback plan on Thursday, February 5th that permits the company to buyback $500.00 million in shares. This buyback authorization permits the company to reacquire up to 8% of its stock through open market purchases. Stock buyback plans are typically an indication that the company’s board believes its shares are undervalued.

Insider Buying and Selling

In related news, insider Siddharth Sitaram sold 2,427 shares of the business’s stock in a transaction that occurred on Friday, April 10th. The shares were sold at an average price of $21.09, for a total transaction of $51,185.43. Following the completion of the transaction, the insider owned 86,705 shares in the company, valued at approximately $1,828,608.45. The trade was a 2.72% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Kira Scherer Wampler sold 9,000 shares of the business’s stock in a transaction that occurred on Thursday, May 7th. The shares were sold at an average price of $26.06, for a total transaction of $234,540.00. Following the transaction, the director owned 19,839 shares of the company’s stock, valued at approximately $517,004.34. This represents a 31.21% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 18,055 shares of company stock valued at $456,061. Corporate insiders own 31.30% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. Vanguard Group Inc. grew its holdings in Doximity by 4.1% during the fourth quarter. Vanguard Group Inc. now owns 13,285,485 shares of the company’s stock valued at $588,281,000 after purchasing an additional 518,916 shares during the period. Aubrey Capital Management Ltd acquired a new position in shares of Doximity in the third quarter valued at approximately $4,572,000. UBS Group AG boosted its holdings in shares of Doximity by 26.5% in the fourth quarter. UBS Group AG now owns 680,260 shares of the company’s stock valued at $30,122,000 after buying an additional 142,408 shares during the period. Blair William & Co. IL boosted its holdings in shares of Doximity by 1,990.7% in the third quarter. Blair William & Co. IL now owns 362,740 shares of the company’s stock valued at $26,534,000 after buying an additional 345,390 shares during the period. Finally, William Blair Investment Management LLC boosted its holdings in shares of Doximity by 11.7% in the third quarter. William Blair Investment Management LLC now owns 5,829,169 shares of the company’s stock valued at $426,404,000 after buying an additional 609,775 shares during the period. Institutional investors and hedge funds own 87.19% of the company’s stock.

Key Headlines Impacting Doximity

Here are the key news stories impacting Doximity this week:

• Positive Sentiment: Doximity said revenue still grew year over year, and its earnings call highlighted strong engagement from AI tool adoption, suggesting the platform is gaining traction with physicians. Doximity Stock Falls on Q4 Earnings Miss, Revenues Beat, Margins Down
• Positive Sentiment: Doximity announced a partnership with Aledade to bring clinical AI tools into value-based care workflows, which could support longer-term adoption and monetization. DOCS Teams Up With Aledade to Bring Clinical AI to Value-Based Care
• Neutral Sentiment: Several articles noted the stock has become technically oversold after a sharp selloff, which could set up a bounce if sentiment improves. Down 25.7% in 4 Weeks, Here’s Why Doximity (DOCS) Looks Ripe for a Turnaround
• Negative Sentiment: Doximity missed quarterly earnings estimates and issued fiscal 2027 revenue guidance below Wall Street expectations, raising concerns that growth is slowing. Doximity, Inc. (DOCS) Q4 2026 Earnings Call Transcript
• Negative Sentiment: Analysts turned more cautious, with multiple firms cutting price targets or downgrading the stock, including Baird, Wells Fargo, BTIG, JPMorgan, Mizuho, BMO, Needham and Truist. DOCS vs. HIMS: Which Stock Is the Better Value Option?
• Negative Sentiment: Investor caution also increased after insider selling was disclosed, even though it was tied to a pre-arranged 10b5-1 plan and tax withholding. Doximity (NYSE:DOCS) Insider Siddharth Sitaram Sells 2,309 Shares

About Doximity

Doximity, trading as DOCS, operates a digital professional network and communications platform designed primarily for clinicians. Headquartered in San Francisco, the company connects physicians, nurse practitioners, physician assistants and other healthcare professionals, providing tools that streamline clinical communication, telehealth delivery and access to specialty-specific medical information. Its platform is positioned as a professional hub where clinicians manage their workflows, stay current with medical news and collaborate securely with peers.

The company’s offerings include secure messaging and video telehealth capabilities that enable clinicians to consult with patients and colleagues while protecting patient information.